Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 418

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 418
---
, to $1,702,559, for the year ended June 30, 2024. This decline is attributable to a combination of volume and price effects: • volume effect: approximately 95.6% of the decline ($116,731) is due to a 6.4% reduction in testing volumes across key areas such as rare diseases, prenatal, and microbiome testing. Reduced customer demand, heightened competition, and evolving market conditions led to fewer tests performed; and • price effect: the remaining 4.4% of the decline ($5,374) is due to a 0.3% decrease in average pricing, which is quoted in U.S. dollars, driven by increased pricing pressures and competitive dynamics in the diagnostics market. In addition to these market -specificdynamics, macroeconomic factors exacerbated the decline. The transition of Argentina’s government from Alberto Fernández to Javier Milei in December 2023 brought significant economic reforms aimed at reducing inflation and stabilizing the economy. These reforms, however, gave rise to pricing volatility and reduced consumer purchasing power within the healthcare sector, further impacting demand for diagnostic products and services. Revenues from the Rewell segment increased by $61,536, or 111.3%, from $55,275 in the year ended June 30, 2023, to $116,811 in the year ended June 30, 2024. This growth is explained as follows: • volume effect: 29.5% of the increase ($18,153) is due to a 32.84% growth in the number of kits sold, reflecting expanded commercialization efforts and improved sales strategies; and

215 • price effect: 70.5% of the increase ($43,383) is due to a 78.49% rise in the average price per kit, which is quoted in U.S. dollars, driven by adjustments in pricing strategies and increased direct -to -consumersales. Overall, approximately 93.6% and 6.4% of total revenues were derived from the Heritas Diagnostics segment and the Rewell segment, respectively, in the year ended June 30, 2024, compared to 97.1% and 3.0%, respectively, in the year ended June 30, 2023. Cost of revenues Cost of revenues decreased by $45,705, or 2.4%, from $1,920,443 in the year ended June 30, 2023, to $